Altimmune (NASDAQ:ALT) Downgraded to Neutral at Guggenheim

Guggenheim cut shares of Altimmune (NASDAQ:ALT) from a buy rating to a neutral rating in a report issued on Monday, MarketBeat.com reports.

ALT has been the subject of a number of other research reports. HC Wainwright reduced their price objective on Altimmune from $15.00 to $12.00 and set a buy rating for the company in a research report on Monday, April 1st. The Goldman Sachs Group initiated coverage on Altimmune in a report on Wednesday, January 24th. They set a neutral rating and a $13.00 price target for the company. Finally, B. Riley reiterated a buy rating and issued a $20.00 price target on shares of Altimmune in a research note on Thursday, March 28th.

Altimmune Stock Performance

Shares of NASDAQ:ALT opened at $6.40 on Monday. The firm has a market capitalization of $453.34 million, a P/E ratio of -3.88 and a beta of 0.05. The stock has a 50 day moving average price of $9.24 and a 200-day moving average price of $7.61. Altimmune has a 52-week low of $2.09 and a 52-week high of $14.84.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Wednesday, March 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.02. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. The business had revenue of $0.04 million during the quarter. On average, equities analysts forecast that Altimmune will post -1.52 EPS for the current fiscal year.

Institutional Trading of Altimmune

Institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC boosted its holdings in shares of Altimmune by 62.0% during the 3rd quarter. Barclays PLC now owns 180,409 shares of the company’s stock valued at $470,000 after acquiring an additional 69,014 shares during the last quarter. Timelo Investment Management Inc. boosted its holdings in Altimmune by 2,597.0% in the fourth quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock worth $9,102,000 after purchasing an additional 779,095 shares during the last quarter. GSA Capital Partners LLP grew its position in Altimmune by 153.1% in the 3rd quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock worth $1,159,000 after purchasing an additional 269,676 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in Altimmune during the 4th quarter valued at $534,000. Finally, Dark Forest Capital Management LP lifted its holdings in shares of Altimmune by 13.4% during the 3rd quarter. Dark Forest Capital Management LP now owns 230,353 shares of the company’s stock valued at $599,000 after buying an additional 27,210 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.